Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C101520
http://purl.obolibrary.org/obo/NCIT_C101520
|
|---|---|
| Preferred Name | FLT3/KIT Kinase Inhibitor AKN-028 |
| Definitions |
An orally bioavailable protein tyrosine kinase inhibitor for FMS-related tyrosine kinase 3 (FLT3; STK1) and stem cell factor receptor (SCFR; KIT), with potential antineoplastic activity. FLT3/KIT kinase inhibitor AKN-028 binds to and inhibits both the wild-type and mutated forms of FLT3 and SCFR. This may result in an inhibition of tumor cell proliferation in cancer cell types that overexpress these receptor tyrosine kinases.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally bioavailable protein tyrosine kinase inhibitor for FMS-related tyrosine kinase 3 (FLT3; STK1) and stem cell factor receptor (SCFR; KIT), with potential antineoplastic activity. FLT3/KIT kinase inhibitor AKN-028 binds to and inhibits both the wild-type and mutated forms of FLT3 and SCFR. This may result in an inhibition of tumor cell proliferation in cancer cell types that overexpress these receptor tyrosine kinases. |
|---|---|
| prefLabel | FLT3/KIT Kinase Inhibitor AKN-028
|
| label | FLT3/KIT Kinase Inhibitor AKN-028
|
| PDQ_Closed_Trial_Search_ID | 731885
|
| code | C101520
|
| prefixIRI | NCIT:C101520
|
| in_subset | |
| Preferred_Name | FLT3/KIT Kinase Inhibitor AKN-028
|
| FDA_UNII_Code | Y66IS3CS0R
|
| Contributing_Source | FDA
|
| Maps_To | FLT3/KIT Kinase Inhibitor AKN-028
|
| CAS_Registry | 1175017-90-9
|
| NCI_Drug_Dictionary_ID | 731885
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 731885
|
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C3852612
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |